Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure
Publication date: November 2026 Source: Gynecologic Oncology, Volume 214 Author(s): Sanghoo Lee, Kyeong-A So, Soyeon Kim, Mi-Kyeong Lee, Yun Hwan Kim, Tae Jin Kim, Mi-Kyung Kim
Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure. // Gynecologic Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0090825826021608?dgcid=rss_sd_all
Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure. Gynecologic Oncology. https://www.sciencedirect.com/science/article/pii/S0090825826021608?dgcid=rss_sd_all
“Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure.” Gynecologic Oncology.
@article{article47482,
title = {Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure},
journal = {Gynecologic Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0090825826021608?dgcid=rss_sd_all}
}